#1 Clinical Trials Search in Europe

Pariglasgene Brecaparvovec

Pariglasgene Brecaparvovec is an innovative gene therapy being studied in clinical trials for the treatment of Glycogen Storage Disease Type Ia (GSDIa). This article explores the ongoing research, potential benefits, and important considerations surrounding this experimental treatment for patients with GSDIa.

Table of Contents

What is Pariglasgene Brecaparvovec?

Pariglasgene brecaparvovec, also known by its product codes DTX401 and AAV8G6PC, is an innovative gene therapy medication designed to treat Glycogen Storage Disease Type Ia (GSDIa)[1]. It is classified as an advanced therapy medicinal product, specifically a gene therapy medicinal product[2].

How Does It Work?

Pariglasgene brecaparvovec works by using a modified virus called adeno-associated virus serotype 8 (AAV8) to deliver a functional copy of the glucose-6-phosphatase (G6Pase) gene to liver cells[1]. This gene is responsible for producing an enzyme that helps break down glycogen (stored sugar) into glucose (usable sugar) in the body. In people with GSDIa, this gene is faulty, leading to an inability to maintain normal blood sugar levels[2].

What Condition Does It Treat?

Pariglasgene brecaparvovec is specifically designed to treat Glycogen Storage Disease Type Ia (GSDIa). This is a rare genetic disorder that affects the body’s ability to break down glycogen, leading to problems with blood sugar regulation and other metabolic issues[1][2].

Clinical Trials and Research

Several clinical trials are being conducted to evaluate the safety and efficacy of pariglasgene brecaparvovec:

  • A long-term follow-up study (Phase 1/2) is assessing the safety and effectiveness of the therapy in adults with GSDIa who have previously received the treatment[1].
  • A Phase 3 randomized, double-blind, placebo-controlled study is evaluating the efficacy and confirming the safety of the treatment in patients 8 years and older with GSDIa[2].
  • A Disease Monitoring Program is tracking long-term safety and effectiveness for at least 10 years after treatment administration[3].

How is It Administered?

Pariglasgene brecaparvovec is administered as a single intravenous (IV) infusion. The dose used in clinical trials is 1.0 × 10^13 genome copies per kilogram of body weight[2]. This one-time treatment is designed to provide long-lasting effects by correcting the underlying genetic cause of GSDIa.

Potential Benefits

The primary goals of this gene therapy are to:

  • Reduce or eliminate dependence on exogenous glucose replacement therapy (such as cornstarch)[2].
  • Improve glucose control and reduce the frequency of hypoglycemic events[2].
  • Enhance the overall quality of life for patients with GSDIa[2].

Safety and Side Effects

As with any medical treatment, safety is a primary concern. The clinical trials are monitoring for various potential side effects, including:

  • Infusion-related reactions, including hypersensitivity[3].
  • Vector-induced hepatic effects (e.g., increased liver enzyme levels)[3].
  • Potential risks associated with AAV therapies, such as malignancy or thrombotic microangiopathy[3].

It’s important to note that the long-term safety profile is still being evaluated through ongoing clinical trials and follow-up studies[3].

Long-Term Follow-Up

Given the nature of gene therapy, long-term monitoring is crucial. A Disease Monitoring Program has been established to track patients for at least 10 years after receiving pariglasgene brecaparvovec[3]. This program will evaluate:

  • Long-term safety and effectiveness of the treatment[3].
  • Pregnancy outcomes in treated patients or their partners[3].
  • Major clinical events and overall patient experience[3].

In conclusion, pariglasgene brecaparvovec represents a promising advancement in the treatment of Glycogen Storage Disease Type Ia. While still under investigation, this gene therapy offers hope for improved quality of life and reduced disease burden for individuals living with this rare genetic disorder. As research progresses, more information about its long-term efficacy and safety will become available.

Aspect Details
Treatment Pariglasgene Brecaparvovec (DTX401)
Condition Glycogen Storage Disease Type Ia (GSDIa)
Mechanism AAV8-mediated gene transfer of Glucose-6-Phosphatase (G6Pase)
Administration Single intravenous infusion
Trial Phases Phase 1/2, Phase 3, and Long-term follow-up
Primary Objectives Evaluate long-term safety and efficacy
Key Endpoints Reduction in cornstarch intake, improved glucose control, quality of life
Safety Monitoring Adverse events, liver effects, malignancy, pregnancy outcomes
Follow-up Duration Up to 10 years post-treatment

FAQ

  • What is Pariglasgene Brecaparvovec? Pariglasgene Brecaparvovec is a gene therapy that uses a modified virus (AAV8) to deliver a functional copy of the glucose-6-phosphatase (G6PC) gene to patients with Glycogen Storage Disease Type Ia. This therapy aims to correct the underlying genetic defect responsible for the condition.
  • How is Pariglasgene Brecaparvovec administered? The therapy is administered as a single intravenous (IV) infusion. In clinical trials, it is given at a specific dose based on the patient's weight, typically measured in genome copies (GC) per kilogram of body weight.
  • What are the main goals of the clinical trials studying Pariglasgene Brecaparvovec? The primary goals are to evaluate the long-term safety and effectiveness of the therapy. Researchers are particularly interested in its ability to reduce or eliminate the need for exogenous glucose replacement therapy, improve glucose control, and enhance the overall quality of life for patients with GSDIa.
  • Who is eligible to participate in these clinical trials? Eligibility varies by study, but generally includes patients aged 8 years and older with a confirmed diagnosis of GSDIa. Participants must meet specific criteria regarding their current treatment regimen, liver health, and ability to comply with study procedures. Some studies are follow-ups for patients who have already received the therapy in previous trials.
  • What are the potential risks and side effects being monitored in these trials? Researchers are closely monitoring for any adverse events, with special attention to infusion-related reactions, liver-related effects, potential malignancies, and impacts on the nervous system. The studies also track pregnancy outcomes in treated patients or their partners to assess any potential risks to fetal development.

Ongoing Clinical Trials on Pariglasgene Brecaparvovec

  • Study on Long-Term Safety and Pregnancy Outcomes of Pariglasgene Brecaparvovec in Patients with Glycogen Storage Disease Type Ia (GSDIa)

    Recruiting

    3 1 1
    Investigated drugs:
    Denmark Germany Italy The Netherlands Spain

  • Study on the Effects of Pariglasgene Brecaparvovec for Adults with Glycogen Storage Disease Type Ia

    Not recruiting

    1 1 1
    Investigated drugs:
    The Netherlands Spain

  • Study of Pariglasgene Brecaparvovec and Prednisolone for Adults with Glycogen Storage Disease Type Ia

    Not recruiting

    3 1 1
    Investigated drugs:
    Denmark Germany Italy The Netherlands Spain

Glossary

  • Glycogen Storage Disease Type Ia (GSDIa): A rare genetic disorder that affects the body's ability to break down stored glucose, leading to problems with blood sugar regulation and other metabolic issues.
  • Gene therapy: A technique that uses genes to treat or prevent disease. In this case, it involves introducing a functional copy of the G6PC gene to correct the genetic defect in GSDIa.
  • AAV8: Adeno-Associated Virus serotype 8, a type of virus modified for use in gene therapy to deliver genetic material to cells.
  • Glucose-6-phosphatase (G6Pase): An enzyme crucial for maintaining blood glucose levels. It is deficient in patients with GSDIa.
  • Exogenous glucose replacement therapy: The current standard treatment for GSDIa, involving regular intake of cornstarch or other forms of glucose to maintain blood sugar levels.
  • Controlled Fasting Challenge (CFC): A test used in clinical trials to assess how long a patient can maintain normal blood glucose levels without eating or receiving glucose supplementation.
  • Continuous Glucose Monitoring (CGM): A method used to track blood glucose levels throughout the day and night, providing a more comprehensive picture of glucose control.
  • Hypoglycemia: Low blood sugar levels, a common concern in GSDIa patients.
  • Genome copies (GC): A measure used to quantify the amount of genetic material in gene therapy doses.
  • Adverse Events of Special Interest (AESIs): Specific medical events that are closely monitored in clinical trials due to their potential significance or relationship to the treatment being studied.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effects-of-pariglasgene-brecaparvovec-for-adults-with-glycogen-storage-disease-type-ia/
  2. http://clinicaltrials.eu/trial/study-of-pariglasgene-brecaparvovec-and-prednisolone-for-adults-with-glycogen-storage-disease-type-ia/
  3. http://clinicaltrials.eu/trial/study-on-long-term-safety-and-pregnancy-outcomes-of-pariglasgene-brecaparvovec-in-patients-with-glycogen-storage-disease-type-ia-gsdia/